Dr Cheryl Blanchard, president and CEO of Anika Therapeutics, discusses the company, technology and developments for future growth in an interview with SmartTRAK.

In a recent interview with SmartTRAK, Dr. Cheryl Blanchard, president and CEO of Anika Therapeutics, discussed the company’s strategic direction, proprietary technology and advancements in its next-generation osteoarthritis (OA) pain management and regenerative solutions.

To find out more about the company, its differentiated technologies, products and growth strategy, click on the following video (26:40 min).

Interview topics by timecode are provided below, as is a link to download a complete transcript of the interview.

Interview Outline by Timecode:

00:20 Introduction to Anika Therapeutics, president and CEO Dr. Cheryl Blanchard and the company’s strategy.
01:14 The US OA Injectables Market and Anika’s next-generation OA pain solution, Cingal.
02:52 Cingal’s advantages and how it fit in the treatment continuum.
04:56 Cingal’s positioning and clinical trials’ progress.
10:47 Marketing communication, commercial and pricing approach and beyond knee OA.
13:42 Hyalofast, Anika’s next-generation cartilage repair solution.
17:25 Anika’s regenerative platform and the Integrity Implant System.
19:54 Cheryl Blanchard’s take on the next major disruptive force.
22:42 Thoughts around healthcare policy changes, tariffs uncertainty and other macro trends.

Click the button below to download and read the complete transcript of SmartTRAK's interview with Dr. Cheryl Blanchard, president and CEO of Anika Therapeutics, conducted by  Freddy Buntoum, SmartTRAK Senior Analyst, Orthobiologics and Regenerative Medicine.

The US Orthobiologics (Orthobio) market performed well during the first quarter of 2023 and looks to be on a solid upswing and shining bright with the rebound of elective procedures as drivers to positive momentum. Q123 saw positive growth in all segments of the US Orthobio market, which closed on high notes, with revenue up +8.9% YoY.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Orthobio Market Recap* are:

• Complete Q123 Orthobio Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Orthobio Companies' News, Revenues, Data, Charts and Market Shares
• US Bone Replacement – Springing Back Into Light
  • Growth Factors/Peptides
  • DBM and Synthetics
• US Cartilage Replacement –The Light Continues To Shine Bright
  • Cellular Grafts
  • Osteochondral Grafts
• US Soft Tissue Replacement – Sunny Days Continue
  • Soft Tissue Patches
  • Tendon Allografts
• US Meniscus Replacement – Sun is Shining Back on The Market

Despite continued healthcare staffing shortages and economic uncertainties, the US Bone Replacement experienced high single-digit percentage growth in Q123 as it benefited from increased utilization, especially in ...

Read the entire Q123 US Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Among the many topics covered in detail in SmartTRAK's comprehensive Q422/FY22 US Joint Fluid Replacement Market Recap* are:

• Complete Q422/FY22 Market Overview and Highlights
• SmartTRAK's Expert Market Analysis and Insights
• All Company News, Revenues, Data, Charts and Shares
• Smooth Waters for Some, Turbulent Rapids for Others in Single-Injection Market
• Which Players are Taking The Wrong Waterway in Multi-Injection Market?
• Who are the Winners of the Multi-injection Kayak Race?
• What Companies Were Left in the Wake in the Multi-injection Segment?
• The Outlook for Joint Fluid Replacement in 2023

On the outlook for 2023 in the US Joint Fluid Replacement market, SmartTRAK expects to see a persistent competitive environment and continued pricing pressure, but the anticipation of ASP stabilization should make for a calmer playing field and enable some to regain market share in certain segments. That said, some unforeseen disruptors may lead to potential internal disruptions like the recent announcement from ...

Read the entire Q422/FY22 US Joint Fluid Replacement Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares. *

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

---

Among the many topics covered in detail in our comprehensive Q422/FY22 OrthoBio Recap* are:

• Complete Q422 Trauma Market Overview and Highlights
• SmartTRAK's Expert Market Analysis and Insights
• All Company News, Revenues, Data, Charts and Shares
• US Bone Replacement
  • Good Momentum as Spine Rebounds and Products Launch
• US Cartilage Replacement
  • Procedure Volumes Stabilizing
• US Soft Tissue Replacement
  
  • Winter Months More Like a Sunny Day Rose Parade
• US Meniscus Replacement 
  • Growth Dampened by a Non-Blooming Group of Small Players

In addition to the previously mentioned market growth drivers, and as SmartTRAK highlighted in its latest trends article, “What Lies Ahead for Orthobiologics in 2023 and Beyond”,* other contributing factors of growth in 2022 and indicators of future growth in the US Orthobio market, included a tremendous level of M&As, strategic alliances and investments in new technologies. Overall, the US Orthobio market performed above expectations and ...

Read the entire Q422 Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares.*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

The interest and demand for regenerative medicine for various conditions and injuries have increased exponentially over the last decade. From January 1, 1990 to December 31, 2012, google searches for regenerative medicine totaled 21,600,000. With increased publicity about stem cells and advancements in cell and gene therapies, biomaterials and tissue engineering, google searches increased nearly ten-fold to 212,000,000 from 1/1/13 to 2/27/23.

• PRP Trends and the Impacts to 2023 and Beyond
  
  • Headwinds in 2023
  • Trends in PRP Clinical Trials
  • Anticipated 2023 US PRP Market Share Standings
• Adipose Trends and the Impacts to 2023 and Beyond
  • Adipose tissue therapy gaining interest in the field of sports medicine
  • Patient demand for minimally-invasive solutions
  • Adipose-derived cell therapies for OA and Degenerative Disc Disease
    

So is regenerative medicine the way of the future? Time will tell, however, SmartTRAK feels that demand and interest by multiple stakeholders, along with recent trends, medical and legal advancements and investments is tipping the scale to ...

To download and read the complete "A Glimpse into 2023: Regen Med Trends" article by Freddy Buntoum, SmartTRAK's Senior Analyst, Orthobiologics and Regenerative Medicine, just click the button below.

CMS Reimbursement changes raging like a beast to belabor several HA market players

For Q322, the true impact of CMS reimbursement changes was blatantly apparent, with the US Joint Fluid Replacement Market showing an overall lackluster revenue performance, with a YoY decline of -4.7% vs Q321, according to SmartTRAK Financial Dashboard. As if the new CMS regulations were not enough, the swing toward negative growth was also driven by hyaluronic (HA) companies battling for product placement, preferred formulary status with private payers, overall inflation, and still to a certain degree, supply chain-related issues stemming from COVID-19 and subsequent waves of the different variants. Aggregate revenue being in the red for the third quarter of 2022 was mainly the result of negative YoY growth across three of the four HA segments. Still, with an anticipated hard push to more positive year-end results, the US Joint Fluid Replacement Market is trending toward achieving on or ever so slightly above  SmartTRAK’s US Joint Fluid Replacement Market Overview revenue projections

Among the many topics covered in detail in our comprehensive Q322 US Joint Fluid Replacement Market Recap* are:

Highlighting the latest research, technology developments and innovations taking place in orthobiologics and regenerative medicine at ICRS 2022

This year the International Cartilage Regenerative & Joint Preservation Society (ICRS) hosted its 16th World Congress in Berlin, Germany, and SmartTRAK covered it. This was the Society’s first in-person meeting since October 2019, and without a doubt, a very exciting moment for ICRS, its members and all who attended the event. For four days, industry stakeholders from around the world converged in Berlin to learn and hear about the latest research, technology developments and innovations taking place in orthobiologics and regenerative medicine. In this article, SmartTRAK gives a recap of some of the main topics presented during the meeting.

Among the many fascinating topics covered in the complete article, which can be downloaded here, are:

• The Role of Extracellular Vesicles 
• Use of Minced Cartilage
• Autologous, Matrix-induced Chondrogenesis 
• Feasibility of Gene Therapy
• Other Therapies of Tomorrow

Mr J. David Owens, President & CEO of BiologicsMD, and Chief Scientific Officer, Dr. Robyn Goforth, discuss the Company’s highly-targeted therapies, a series of recombinant fusion proteins designed to treat hair loss and severe bone disorders, in an interview with SmartTRAK.

In an interview with SmartTRAK, BiologicsMD President & CEO J. David Owens and CSO Dr. Robyn Goforth discuss BiologicsMD’s innovative highly-targeted treatments for severe bone disorders and hair loss diseases.

To find out more about this early-stage company, the science behind highly-targeted therapies, and two of its lead compounds, click on the following video to listen to the full interview (29:10 min). A link to download a complete transcript of the interview is also provided below.

For Q122, US Joint Fluid Replacement market players continued on a running growth, which did not seem too disrupted by the COVID Omicron variant. Furthermore, some players shared that despite physicians’ offices not yet running at 100% levels, company sales representatives were able to hold face-to-face visits and secure new orders.

From the impact of stringent regulations to the shift toward new indications and rising market segments, SmartTRAK explores some of the trends to watch for in 2022 and beyond.

Orthopedic regenerative medicine therapy as an emerging area of science holds great promise for treating and promoting faster healing in a variety of injuries. There is also a belief among some scientists and industry stakeholders that it may hold the key to halting or reversing degenerative chronic conditions through self-healing. In a previous article, SmartTRAK had highlighted several challenges that Regenerative Medicine therapies would need to overcome to become a fully viable business and recognized treatment solution for patients. In 2021, businesses, societies and health care systems across the world continued to experience disruptions from the COVID-19 pandemic and its subsequent waves of variants. Furthermore, much greater scrutiny and tougher regulations for some of the injectable regenerative medicine therapies were put into place. The start of 2022 is also not quite as “rosy” as most had hoped for ...